The interaction between serum endostatin , estimated glomerular filtration rate ( eGFR ) and predefined endpoints , including the primary endpoint ( CV death , nonfatal myocardial infarction , nonfatal stroke ; n = 397 ) , all-cause mortality ( n = 410 ) , CV death ( n = 335 ) or the coronary endpoint ( n = 317 ) , was evaluated in 1,390 patients > 60 years of age with ischemic systolic HF in the Controlled Rosuvastatin Multinational Trial in HF ( CORONA ) population , who were randomly assigned to 10 mg rosuvastatin or placebo .